National Institute of Allergy and Infectious Diseases, National Institutes of Health - Monday, Jan 27, 2003
Walter Mitton, (301) 402-1663, mitton@niaid.nih.gov

By investigating the ability of combat-ready white blood cells (WBCs) to ingest and kill GAS, researchers have discovered new insights into how this disease-causing bacteria can evade destruction by the immune system. The research is being published this week in the Online Early Edition of the Proceedings of the National Academy of Sciences,USA at http://www.pnas.org/papbyrecent.shtml .

Frank DeLeo, Ph.D., tenure-track investigator in the Laboratory of Human Bacterial Pathogenesis, National Institute of Allergy and Infectious Diseases (NIAID), Rocky Mountain Laboratories in Hamilton, MT, directed the study. ôThis is the first genome-scale look at GAS genes that are differentially expressed during interaction with the human innate immune system,ö he says. ôWe are excited about our findings and how they may lead to further investigation of therapeutics that can protect us from this major human pathogen.ö According to Dr. DeLeo, this type of study is the next logical application of microbial genomics.

An estimated 15 million new cases of noninvasive GAS infections occur in the United States each year, with a direct health care cost of $2 billion. The noninvasive and milder types of infection, primarily strep throat and skin infections, occur mostly in children between the ages of 5 and 14 years old. Elementary school-aged children are at highest risk for noninvasive disease. In 2000, the reported incidence of the more serious invasive GAS disease, which includes streptococcal toxic shock syndrome (STSS), cellulitis, pneumonia, bacteremia and necrotizing fasciitis (flesh-eating disease), was 8,800 cases and 1,000 deaths. The elderly, immunosuppressed, persons with chronic cardiac or respiratory disease or diabetes, African Americans, American Indians and persons with skin lesions (for example, children with chickenpox and intravenous drug users) have increased risk for GAS invasive disease.

Some GAS infections may be asymptomatic, and if untreated, can lead to life-threatening infections. With an early diagnosis, however, noninvasive GAS can be successfully treated with antibiotics. On the other hand, it is much more difficult to treat invasive GAS disease, and these infections are associated with high morbidity and mortality.

By examining the interaction between disease-fighting human WBCs and a type of GAS that causes abundant disease in North America and Western Europe, the NIAID scientists have discovered how GAS elicits its own genome-wide protective response to evade destruction by the human immune system. The two opponents, WBCs and GAS, met face to face in experiments conducted by Dr. DeLeo, James Musser, M.D., Ph.D., chief of the Laboratory of Human Bacterial Pathogenesis, and their colleagues.

For their study, the researchers used human WBCs called polymorphonuclear leukocytes (PMNs), an essential component of the immune systemÆs defense against foreign invaders. These microbe-eating cells are in a class of cells termed phagocytes, which stand ready to seek and destroy foreign substances such as bacteria. During battle with most foreign microbes, PMNs successfully ôeatö invading predators, a scientific process called phagocytosis. After microbes are engulfed, PMNs produce deadly oxygen radicals, such as hydrogen peroxide and hypoclorous acid (the active ingredient in household bleach), and release toxic granules to kill the enemy. Normally, this defense tactic can defeat most foreign invaders, but it is ineffective against highly evolved GAS bacterium.

The scientists examined how PMNs from healthy individuals ingest and kill GAS and tested their hypothesis that GAS revs up or slows down the production of specific factors to evade the innate immune system. The study indicates that GAS becomes more resilient to ingestion and killing by PMNs over time or it produces factors that alter normal PMN function. This resiliency is demonstrated by the increased expression of various GAS genes associated with the bacteriaÆs virulence and cell wall repair as well as genes that encode proteins likely to promote immune evasion.

The studyÆs lead author, Jovanka Voyich, Ph.D., states, ôOur study identifies potential vaccine candidates and new targets for therapy interventions designed to control GAS infections.ö The scientists hope that this new knowledge in combination with their earlier GAS research will lead to further investigation of how GAS evades destruction by our innate immune system and will inevitably spur the discovery of vaccine therapies and antibiotics that can prevent and treat invasive and noninvasive strains of this bacterium.

NIAID is a component of the National Institutes of Health (NIH). NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies.
030127
NI030104

Published 2003 - National Institute of Allergy and Infectious Diseases . All material contained in this report is in the public domain and may be used and reprinted without special permission; citation to source, however, is appreciated.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .